{
 "id": "eprebwyhes",
 "slug": "gemcitabine-monotherapy-regimen",
 "title": "Gemcitabine monotherapy regimen",
 "updated": "2026-10-15",
 "topic_path": [
  {
   "id": "life",
   "label": "Life and health",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life"
  },
  {
   "id": "life.health",
   "label": "Human health and medicine",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.health"
  },
  {
   "id": "life.health.medicines",
   "label": "Medicines and therapeutics",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines"
  },
  {
   "id": "life.health.medicines.cancer-chemotherapy",
   "label": "Cancer chemotherapy and regimens",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines.cancer-chemotherapy"
  },
  {
   "id": "life.health.medicines.cancer-chemotherapy.antimetabolite-and-fluoropyrimidine-regimens",
   "label": "Antimetabolite and fluoropyrimidine regimens",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines.cancer-chemotherapy.antimetabolite-and-fluoropyrimidine-regimens"
  }
 ],
 "geo": [
  {
   "id": "geo.nongeo.t1946.life.health.medicines.cancer-chemotherapy",
   "label": "Non-geographic · 1946 to 2000: Cancer chemotherapy and regimens",
   "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.medicines.cancer-chemotherapy",
   "path": [
    {
     "id": "geo.nongeo",
     "label": "Non-geographic",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo"
    },
    {
     "id": "geo.nongeo.t1946",
     "label": "Non-geographic · 1946 to 2000",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946"
    },
    {
     "id": "geo.nongeo.t1946.life",
     "label": "Life and health",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life"
    },
    {
     "id": "geo.nongeo.t1946.life.health",
     "label": "Human health and medicine",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health"
    },
    {
     "id": "geo.nongeo.t1946.life.health.medicines",
     "label": "Medicines and therapeutics",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.medicines"
    },
    {
     "id": "geo.nongeo.t1946.life.health.medicines.cancer-chemotherapy",
     "label": "Cancer chemotherapy and regimens",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.medicines.cancer-chemotherapy"
    }
   ]
  }
 ],
 "excerpt": "Gemcitabine monotherapy is a chemotherapy regimen in which gemcitabine is given intravenously alone, approved in 1996 for advanced pancreatic cancer and now mainly used in elderly or frail patients.",
 "snippet": "Gemcitabine monotherapy is a chemotherapy regimen in which gemcitabine is given intravenously alone, approved in 1996 for advanced pancreatic cancer and now mainly used in elderly or frail patients.",
 "node": "life.health.medicines.cancer-chemotherapy.antimetabolite-and-fluoropyrimidine-regimens",
 "markdown": "# Gemcitabine monotherapy regimen\n\nGemcitabine monotherapy is a chemotherapy regimen in which the drug gemcitabine, a deoxycytidine analog, is given intravenously as a single agent without other anticancer drugs. In the United States, gemcitabine injection is indicated as first-line treatment for patients with locally advanced (non-resectable Stage II or III) or metastatic (Stage IV) adenocarcinoma of the pancreas, including patients previously treated with fluorouracil.<sup>[1](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06dd9d40-74fc-4409-93b1-a46be7126331)</sup> In Europe, monotherapy can be considered in elderly patients or those with performance status 2,<sup>[2](https://www.medicines.org.uk/emc/medicine/32183/spc)</sup> and this is the population in which it remains standard today.<sup>[3](https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/97305/79036)</sup> The drug was first approved for clinical use in the UK in 1995 and by the FDA for pancreatic cancer in 1996.<sup>[4](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1702720/full)</sup>\n\n| Key fact | Detail |\n|---|---|\n| Approved single-agent use | Locally advanced or metastatic pancreatic adenocarcinoma, first-line and after fluorouracil<sup>[1](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06dd9d40-74fc-4409-93b1-a46be7126331)</sup> |\n| Pancreatic dosing | 1000 mg/m² over 30 minutes once weekly for 7 weeks, one-week rest, then 3 weekly doses per 28-day cycle<sup>[1](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06dd9d40-74fc-4409-93b1-a46be7126331)</sup> |\n| Mechanism | dFdCDP inhibits ribonucleotide reductase; dFdCTP incorporation into DNA causes masked chain termination<sup>[1](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06dd9d40-74fc-4409-93b1-a46be7126331)</sup> |\n| Pivotal trial | Median survival 5.65 vs 4.41 months versus 5-FU; clinical benefit 23.8% vs 4.8%<sup>[5](https://europepmc.org/article/MED/9196156)</sup> |\n| Bested by combination | Nab-paclitaxel plus gemcitabine: median overall survival 8.5 vs 6.7 months (MPACT)<sup>[6](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1838482/full)</sup> |\n| Ready-to-infuse form | Infugem, gemcitabine in sodium chloride injection in pre-filled bags<sup>[7](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208313s007lbl.pdf)</sup> |\n| Current niche | Elderly patients or ECOG performance status 2<sup>[2](https://www.medicines.org.uk/emc/medicine/32183/spc)</sup> |\n\n## How it works\n\nGemcitabine (2',2'-difluorodeoxycytidine; dFdC) is a nucleoside analog structurally similar to cytosine arabinoside.<sup>[8](https://doi.org/10.1002/%28sici%291097-0142%2819960801%2978:3+)</sup> It enters cells through nucleoside transporters, and deoxycytidine kinase (DCK) catalyzes the initial, rate-limiting phosphorylation to the monophosphate (dFdCMP); further phosphorylation by CMPK1 and NDPK yields the diphosphate (dFdCDP) and triphosphate (dFdCTP).<sup>[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC4189987/)</sup> The diphosphate inhibits ribonucleotide reductase, the enzyme that generates deoxynucleoside triphosphates for DNA synthesis, lowering deoxynucleotide pools including dCTP.<sup>[1](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06dd9d40-74fc-4409-93b1-a46be7126331)</sup> The triphosphate competes with dCTP for incorporation into DNA; after a gemcitabine nucleotide is incorporated, only one additional nucleotide is added before DNA synthesis stops.<sup>[1](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06dd9d40-74fc-4409-93b1-a46be7126331)</sup> Because dFdCTP sits at a non-terminal position, proof-reading 3'5'-exonuclease cannot detect and repair it, a process called masked DNA chain termination, which leads to apoptosis.<sup>[10](https://go.drugbank.com/drugs/DB00441)</sup> The diphosphate effect also lowers dCTP, which favors further gemcitabine incorporation; these self-potentiating effects are not present with cytarabine.<sup>[10](https://go.drugbank.com/drugs/DB00441)</sup> About 90% of intracellular gemcitabine is inactivated by cytidine deaminase (CDA) to 2',2'-difluorodeoxyuridine (dFdU).<sup>[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC4189987/)</sup>\n\n## How it is done\n\nFor pancreatic cancer, the labeled single-agent schedule is 1000 mg/m² infused over 30 minutes once weekly for the first 7 weeks, followed by one week of rest, then once weekly for 3 weeks of each 28-day cycle.<sup>[1](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06dd9d40-74fc-4409-93b1-a46be7126331)</sup> For other labeled indications the schedules differ, though these indications are treated with gemcitabine in combination rather than alone.<sup>[1](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06dd9d40-74fc-4409-93b1-a46be7126331)</sup>\n\nThe schedule carries a boxed warning: prolonging the infusion beyond 60 minutes or dosing more frequently than weekly increased clinically significant hypotension, severe flu-like symptoms, myelosuppression, and asthenia.<sup>[1](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06dd9d40-74fc-4409-93b1-a46be7126331)</sup> For specified hematologic toxicity the dose is reduced to 75% of the original cycle initiation dose, and for severe grade 3 or 4 non-hematologic toxicity (other than nausea and vomiting) treatment is withheld or decreased.<sup>[2](https://www.medicines.org.uk/emc/medicine/32183/spc)</sup> [Gemcitabine](https://www.edgepedia.org/gemcitabine) should be used with caution in hepatic or renal insufficiency, because clinical studies provide insufficient information for clear dose recommendations in these populations.<sup>[2](https://www.medicines.org.uk/emc/medicine/32183/spc)</sup>\n\nTwo formulations are in use. The original Gemzar is gemcitabine for injection (NDA 020509); Infugem (NDA 208313) is a 505(b)(2) ready-to-infuse solution of gemcitabine in sodium chloride, supplied in 10 sizes of single-dose pre-filled bags at 10 mg/mL, with a dose-banding approach that rounds doses to within 5% of the body-surface-area-calculated dose.<sup>[11](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208313Orig1s000MedR.pdf)</sup> The Infugem label states the drug is not compatible with infusion bags other than those supplied.<sup>[7](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208313s007lbl.pdf)</sup>\n\n## Origin\n\nGemcitabine was first approved for clinical use in the UK in 1995 and by the FDA for pancreatic cancer in 1996.<sup>[4](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1702720/full)</sup> The reference product, Gemzar (gemcitabine for injection, NDA 020509), was originally approved on May 15, 1996.<sup>[11](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208313Orig1s000MedR.pdf)</sup> The pivotal evidence for single-agent use came from a randomized trial reported by [H. A. Burris](https://www.edgepedia.org/howard-a-burris) and colleagues in the Journal of Clinical Oncology in 1997.<sup>[12](https://doi.org/10.1200/jco.1997.15.6.2403)</sup> In that trial, 126 patients with advanced symptomatic pancreatic cancer were randomized to gemcitabine 1000 mg/m² weekly for 7 weeks then weekly for 3 weeks of each 4-week cycle, or fluorouracil 600 mg/m² once weekly.<sup>[5](https://europepmc.org/article/MED/9196156)</sup> The primary measure was clinical benefit response, a composite of analgesic consumption, pain intensity, Karnofsky performance status, and weight, requiring sustained improvement of at least 4 weeks in one parameter without worsening in others.<sup>[5](https://europepmc.org/article/MED/9196156)</sup>\n\n## Variants\n\nThe weekly schedule with a rest week was fixed early: preclinical and phase I work established 800 to 1000 mg/m² given weekly for 3 weeks every 4 weeks as the standard for phase II studies, chosen for activity and acceptable tolerability.<sup>[8](https://doi.org/10.1002/%28sici%291097-0142%2819960801%2978:3+)</sup> Indication-specific variants of the weekly schedule followed. In biliary tract cancer, the UK ABC-01 randomized phase II trial used gemcitabine 1000 mg/m² on days 1, 8, and 15 of each 28-day cycle in its single-agent arm.<sup>[13](https://pmc.ncbi.nlm.nih.gov/articles/PMC2736816/)</sup> A phase III pancreatic trial used a reduced 900 mg/m² dose on days 1, 8, and 15 every 4 weeks.<sup>[14](https://www.nature.com/articles/6603301)</sup> The formulation variant is the ready-to-infuse Infugem bag described above.<sup>[11](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208313Orig1s000MedR.pdf)</sup>\n\n## Applications\n\nSingle-agent efficacy is best quantified in pancreatic cancer. In the pivotal trial, clinical benefit response was 23.8% for gemcitabine versus 4.8% for 5-FU (P = .0022); median survival was 5.65 versus 4.41 months (P = .0025), and 12-month survival was 18% versus 2%.<sup>[5](https://europepmc.org/article/MED/9196156)</sup> In a phase II trial in 5-FU-refractory pancreatic cancer, 17 of 63 patients attained a clinical benefit response with a median duration of 14 weeks, and median survival was 3.85 months.<sup>[15](https://europepmc.org/article/MED/8805925)</sup> In a later phase III monotherapy arm (900 mg/m² days 1, 8, 15), the overall response rate was 10% (95% CI 2.97 to 17.03), median survival 6.5 months, one-year survival 21.8%, and median time to progression 2.9 months.<sup>[14](https://www.nature.com/articles/6603301)</sup> In a retrospective cohort of 167 patients treated at Polish centers in 2017 to 2022, median overall survival was 6.1 months, median progression-free survival 4.2 months, and one-year survival 24.5%.<sup>[3](https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/97305/79036)</sup> For biliary tract cancer, the monotherapy dosing schedule,<sup>[13](https://pmc.ncbi.nlm.nih.gov/articles/PMC2736816/)</sup> but no published single-agent response or survival figures for biliary tract, NSCLC, or breast cancer are available here; in those diseases the labeled role of gemcitabine is in combination regimens.<sup>[1](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06dd9d40-74fc-4409-93b1-a46be7126331)</sup>\n\n## Limitations and alternatives\n\nThe Infugem label carries a boxed warning for schedule-dependent toxicity and warnings for myelosuppression, severe cutaneous adverse reactions, pulmonary toxicity and respiratory failure, hemolytic uremic syndrome, hepatic toxicity, capillary leak syndrome, and posterior reversible encephalopathy syndrome.<sup>[7](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208313s007lbl.pdf)</sup> In the Polish cohort, grade 3 or 4 adverse events occurred in 20% of patients, most commonly thrombocytopenia and neutropenia, and 5% of patients discontinued treatment because of toxicity.<sup>[3](https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/97305/79036)</sup> On infusion duration the published sources disagree: DrugBank states that the antineoplastic effects of gemcitabine are enhanced through prolonged infusion time rather than higher dosage,<sup>[10](https://go.drugbank.com/drugs/DB00441)</sup> while the FDA labels warn that prolongation beyond 60 minutes increased clinically significant hypotension, severe flu-like symptoms, myelosuppression, and asthenia.<sup>[1](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06dd9d40-74fc-4409-93b1-a46be7126331)</sup>\n\nResistance is attributed to decreased expression of the activation enzyme deoxycytidine kinase, increased degradation, decreased nucleoside transport of drug into cells, and increased expression of RRM1.<sup>[16](https://aacrjournals.org/clincancerres/article/16/1/320/197638/Single-Nucleotide-Polymorphisms-of-Gemcitabine)</sup> Two meta-analyses concluded that high [SLC29A1](https://www.edgepedia.org/slc29a1) (hENT1) protein level is prognostic of improved survival in patients given gemcitabine.<sup>[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC4189987/)</sup>\n\nAgainst combinations, monotherapy is the weaker option for fit patients: in MPACT, nab-paclitaxel plus gemcitabine gave a median overall survival of 8.5 months versus 6.7 months for gemcitabine alone.<sup>[6](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1838482/full)</sup> ESMO and NCCN guidelines recommend multidrug regimens ([FOLFIRINOX](https://www.edgepedia.org/folfirinox), nab-paclitaxel plus gemcitabine) for patients in good condition and gemcitabine monotherapy for those with ECOG performance status 2.<sup>[3](https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/97305/79036)</sup> The 2024 ALPACA trial found that alternating cycles of nab-paclitaxel plus gemcitabine with gemcitabine-alone cycles after three induction cycles gave similar overall survival to continuous combination treatment with improved tolerability.<sup>[17](https://www.thelancet.com/journals/langas/article/PIIS2468-1253%2824%2900197-3/abstract)</sup> The DPCG-01 randomized phase II trial is testing full-dose gemcitabine monotherapy (1000 mg/m² weekly) against reduced-dose gemcitabine 800 mg/m² plus nab-paclitaxel 100 mg/m² in vulnerable patients not candidates for full-dose combination chemotherapy.<sup>[18](https://bmccancer.biomedcentral.com/articles/10.1186/s12885-023-11035-6)</sup>\n\n## References\n\n1. [GEMCITABINE injection, solution, DailyMed label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06dd9d40-74fc-4409-93b1-a46be7126331)\n2. [Gemcitabine 10 mg/ml solution for infusion, Summary of Product Characteristics (emc)](https://www.medicines.org.uk/emc/medicine/32183/spc)\n3. [Systemic treatment of patients with advanced pancreatic cancer, is there still a place for gemcitabine in the first-line setting? Experience of Polish oncology centers](https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/97305/79036)\n4. [Clinical application and drug resistance mechanism of gemcitabine (Frontiers in Cell and Developmental Biology, 2025)](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1702720/full)\n5. [Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial (Burris et al., 1997)](https://europepmc.org/article/MED/9196156)\n6. [Nimotuzumab combined with gemcitabine and nab-paclitaxel as first-line therapy for advanced pancreatic cancer: a single-arm, single-center Phase II prospective study (Frontiers in Medicine, 2026)](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1838482/full)\n7. [INFUGEM (gemcitabine in sodium chloride injection) Prescribing Information, revised 2024](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208313s007lbl.pdf)\n8. [(sici)1097 0142(19960801)78:3+ (doi.org)](https://doi.org/10.1002/%28sici%291097-0142%2819960801%2978:3+)\n9. [PharmGKB summary: Gemcitabine Pathway](https://pmc.ncbi.nlm.nih.gov/articles/PMC4189987/)\n10. [DrugBank: Gemcitabine](https://go.drugbank.com/drugs/DB00441)\n11. [FDA Medical Review for NDA 208313 (Infugem)](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208313Orig1s000MedR.pdf)\n12. [H A Burris and colleagues (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.. Journal of Clinical Oncology.](https://doi.org/10.1200/jco.1997.15.6.2403)\n13. [Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study](https://pmc.ncbi.nlm.nih.gov/articles/PMC2736816/)\n14. [A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer | British Journal of Cancer](https://www.nature.com/articles/6603301)\n15. [A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer](https://europepmc.org/article/MED/8805925)\n16. [Single Nucleotide Polymorphisms of Gemcitabine Metabolic Genes and Pancreatic Cancer Survival and Drug Toxicity (Clinical Cancer Research)](https://aacrjournals.org/clincancerres/article/16/1/320/197638/Single-Nucleotide-Polymorphisms-of-Gemcitabine)\n17. [abstract (thelancet.com)](https://www.thelancet.com/journals/langas/article/PIIS2468-1253%2824%2900197-3/abstract)\n18. [A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01) (BMC Cancer, 2023)](https://bmccancer.biomedcentral.com/articles/10.1186/s12885-023-11035-6)\n\n---\n*Topic: Encyclopedia › Life and health › Human health and medicine › Medicines and therapeutics › Cancer chemotherapy and regimens › Antimetabolite and fluoropyrimidine regimens*\n\n*Initially written Sep 29, 2026 · Edited: Oct 15, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n",
 "same_as": [],
 "url": "https://www.edgepedia.org/gemcitabine-monotherapy-regimen",
 "markdown_url": "https://www.edgepedia.org/gemcitabine-monotherapy-regimen.md",
 "license": {
  "name": "Edgepedia Community License 1.0",
  "url": "https://www.edgepedia.org/edgepedia/license",
  "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.",
  "spdx": "LicenseRef-Edgepedia-Community-1.0"
 },
 "credit": "\"Gemcitabine monotherapy regimen\", Edgepedia (EdgeChat), https://www.edgepedia.org/gemcitabine-monotherapy-regimen. Edgepedia Community License 1.0.",
 "credit_md": "\"[Gemcitabine monotherapy regimen](https://www.edgepedia.org/gemcitabine-monotherapy-regimen)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/gemcitabine-monotherapy-regimen](https://www.edgepedia.org/gemcitabine-monotherapy-regimen). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).",
 "credit_html": "\"<a href=\"https://www.edgepedia.org/gemcitabine-monotherapy-regimen\">Gemcitabine monotherapy regimen</a>\", Edgepedia (EdgeChat), <a href=\"https://www.edgepedia.org/gemcitabine-monotherapy-regimen\">https://www.edgepedia.org/gemcitabine-monotherapy-regimen</a>. <a href=\"https://www.edgepedia.org/edgepedia/license\">Edgepedia Community License 1.0</a>.",
 "speakable": "Gemcitabine monotherapy is a chemotherapy regimen in which gemcitabine is given intravenously alone, approved in 1996 for advanced pancreatic cancer and now mainly used in elderly or frail patients."
}